Notice of Proposed Sale · 144
Stevanato Group S.p.A.
STVNNYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Stevanato Group S.p.A.
- Issuer CIK
- 0001849853
- SEC file number
- 001-40618
- Phone
- 39 049 9318173
- Person for whose account securities are to be sold
- Dal Lago Marco
- Relationships to issuer
- Chief Financial Officer
- Street
- PIOMBINO DESE (PD) VIA MOLINELLA, 17
- City
- PADUA
- State / country code
- L6
- Postal code
- 35017
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Ordinary Shares | 4,209 | 84,554.60 | 302,842,536 | 08/07/2026 | NYSE | Citigroup Global Markets, Inc |
Broker / market maker — proposed row 1, entry 1
- Name
- Citigroup Global Markets, Inc
- Street
- 390 Greenwich St
- City
- New York
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 08/06/2026 | Restricted stock Vesting | Stevanato Group | 4,209 | N | 08/07/2026 | Services Rendered |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Shares sold were to cover obligations pursuant to the vesting and settlement of equity awards. Section 3 e number of shares or units outstanding is from the filed 20f from March 2026
Notice signature
- Notice date
- 08/07/2026
- Signed
- Conformed Signature On File
Company context
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.